Background: A New Player in Neuropsychiatry

On November 26, 2024, NeuroVance Therapeutics emerged from stealth mode, announcing a $40 million Series A funding round led by Arch Venture Partners and Third Rock Ventures. The Boston-based startup is developing targeted therapies for treatment-resistant depression (TRD), a condition affecting millions who do not respond to conventional antidepressants.

The company’s lead candidate, NV-101, is a small molecule modulator of glutamatergic signaling, designed to restore synaptic plasticity in key brain regions. Preclinical data suggest rapid onset of action and durable effects, positioning NV-101 as a potential alternative to ketamine-based therapies.

Leadership Spotlight: A Team with Deep Neuroscience Roots

NeuroVance is helmed by Dr. Maya Ellison, former VP of neuroscience at Biogen, who brings over two decades of CNS drug development experience. Other key hires include:

• Dr. Leo Tran, CSO, previously led neuropharmacology at Sage Therapeutics
• Sarah Kim, COO, formerly with Janssen’s neuropsychiatry division
• Board Members: Include Dr. Thomas Insel, former director of NIMH, and biotech veteran Dr. Sheila Patel

Their combined expertise spans translational neuroscience, regulatory strategy, and commercial launch planning.

Funding Strategy and Investor Vision

• Use of Funds: IND-enabling studies for NV-101, expansion of pipeline assets, and biomarker development
• Investor Commentary:

“NeuroVance is tackling one of the most urgent unmet needs in mental health. Their science is bold, and their team is built to execute,” said Robert Nelsen, co-founder of Arch Venture Partners.

What’s Next?

• IND filing expected mid-2025
• Phase I trial planned for late 2025
• Exploratory programs in bipolar depression and PTSD underway